Online first
Case report
Published online: 2024-11-28
New-onset pulmonary arterial hypertension related to dasatinib therapy.
Abstract
One of the causes of pulmonary hypertension are medications, including that for chronic myeloid leukemia. Our case allows us to draw attention to dasatinib as one of the drugs causing the development of pulmonary hypertension.
Keywords: dasatinibpulmonary hypertensionchronic myeloid leukemia
References
- Preda M, Seferian A, Jutant EM, et al. Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension. 2018; 17(2): 69–74.
- Özgür Yurttaş N, Eşkazan AE. Dasatinib-induced pulmonary arterial hypertension. Br J Clin Pharmacol. 2018; 84(5): 835–845.
- Minami M, Arita T, Iwasaki H, et al. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol. 2017; 177(4): 578–587.
- El-Dabh A, Acharya D. EXPRESS: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ. 2019 [Epub ahead of print]; 9(3): 2045894019865704.
- Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016; 126(9): 3207–3218.
- Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J. 2016; 48(5): 1517–1519.
- Quilot FM, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J. 2016; 47(2): 676–679.
